Answers are grounded in this paper and cite their sources.
Identification of driver mutations in tumors is an extremely important task in oncology for the choice of treatment strategy and assessment of therapy efficacy. In many cases, especially in disease monitoring, there is a need to detect a small number of copies of the mutant allele against the background of excessive content of wild-type DNA. In this work we investigated the possibilities of highly sensitive detection of mutations in IDH1 and IDH2 genes at suppression of wild-type DNA amplification using oligomers of “locked” nucleic acid (LNA) with subsequent hybridization of fluorescently labeled polymerase chain reaction (PCR) product on a biological microchip (biochip). The limit of detection of mutant DNA is 0.1% in the wild-type DNA background. The effectiveness of this approach is demonstrated by analyzing 26 samples of chondroid tumors and glial brain tumors with low representation of the mutant allele, previously undetected mutations R132C, R132L and R132H were identified in three cases.
No takes yet. Share an insight, caveat, or question.
Varachev et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: